Tuesday, December 13, 2011

One-on-One with Genomic Health's Steven Shak

Genomic Health Inc. will roll out another version of its Oncotype DX test this month, helping women with a less risky but tough-to-diagnose type of breast cancer avoid harmful radiation treatment.
The Redwood City company (NASDAQ: GHDX) said a recent study showed that the new test for patients with ductal carcinoma in situ of the breast, or DCIS, is better than traditional clinic and pathologic measures predicting recurrence of the localized cancer or the likelihood of developing a new invasive breast cancer.
It’s far from the only thing Genomic Health has been focusing on.
I spoke with Steven Shak, Genomic Health’s chief medical officer, last month about Oncotype Dx, Genomic Health’s strategy and what’s next in breast, colon and prostate cancer testing.

No comments:

Post a Comment